A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

@article{Hammer1997ACT,
  title={A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.},
  author={Scott M. Hammer and Kathleen E. Squires and Michael D. Hughes and J M Grimes and Lisa M. Demeter and Judith S. Currier and Joseph J. Eron and Judith Feinberg and Henry H. Balfour and Lawrence R. Deyton and Jeffrey A. Chodakewitz and Margaret A. Fischl},
  journal={The New England journal of medicine},
  year={1997},
  volume={337 11},
  pages={
          725-33
        }
}
BACKGROUND The efficacy and safety of adding a protease inhibitor to two nucleoside analogues to treat human immunodeficiency virus type 1 (HIV-1) infection are not clear. We compared treatment with the protease inhibitor indinavir in addition to zidovudine and lamivudine with treatment with the two nucleosides alone in HIV-infected adults previously treated with zidovudine. METHODS A total of 1156 patients not previously treated with lamivudine or protease inhibitors were stratified… 

Figures and Tables from this paper

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
TLDR
In this trial of the initial treatment of HIV-1 infection, the triple-nucleoside combination of abacavir, zidovudine, and lamivudine was virologically inferior to a regimen containing efavirenz and two or three nucleosides.
Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection
TLDR
Long-term HIV therapy with efavirenz, zidovudine, lamivudine or indinavir-containing regimens provides significantly greater antiviral activity and tolerability than a regimen of indinavIR,ZidovUDine plus lamivUDine.
Indinavir: a review of its use in the management of HIV infection.
TLDR
Indinavir is a protease inhibitors with well documented efficacy when used as part of combined therapy in patients with HIV infection, and both US and UK treatment guidelines continue to recommend protease inhibitor-based regimens including indinavir as a first-line option.
Durable HIV-1 Suppression with Indinavir after Failing Lamivudine-Containing Double Nucleoside Therapy: A Randomized Controlled Trial
TLDR
The long-term HIV-1 suppression observed in this study is remarkable, as adding a single antiretroviral agent to a failing regimen goes against current notions of adequate therapy.
Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression
TLDR
The safety, tolerability, and efficacy of the four-nucleoside regimen were not significantly different from the efavirenz-containing regimen, and pilot data support further investigation of the quadruple-nuclear regimen.
A Randomized, Placebo-Controlled Trial of Abacavir Intensification in HIV-1–Infected Adults With Virologic Suppression on a Protease Inhibitor–Containing Regimen
TLDR
The strategy of intensification with abacavir in patients who are virologically suppressed on a stable antiretroviral regimen does not confer a clinical or virologic benefit.
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients
TLDR
The triple nucleoside regimen utilized may be less likely to result in viral suppression to < 50 copies/ml, while the nevirapine-based regimen is associated with a lower increase in CD4 T lymphocytes.
The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.
TLDR
The combination of stavudine plus didanosine reduced plasma HIV-1 RNA concentrations and increased CD4 cell counts more effectively than did the combination of zidovudineplus lamivudine or the regimen alternating both combinations.
Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group.
TLDR
Evaluation of long-term changes, the average of 40- and 48-week HIV plasma RNA, demonstrated that lamivudine and zidovudine provided significantly greater virologic suppression compared with stavudine.
Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team.
TLDR
A change in antiretroviral therapy to a protease inhibitor-containing regimen was associated with a virological response rate of approximately 50% for this patient population.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 51 REFERENCES
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
TLDR
Antiretroviral therapy can improve survival in patients with 200 to 500 CD4 cells per cubic millimeter and is superior to treatment with zidovudine alone, although the benefits were limited to those without previous treatment.
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
TLDR
In most HIV-infected patients with prior antiretroviral therapy, the combination of indinavir, zidovudine, and lamivudine reduces levels of HIV RNA to less than 500 copies per milliliter for as long as one year.
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.
TLDR
Both the risk of the progression of HIV disease and the efficacy of antiretroviral therapy are strongly associated with the plasma level of HIV RNA and with the viral phenotype.
Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.
TLDR
In HIV-infected patients with little or no prior antiretroviral therapy, treatment with a combination of lamivudine and zidovudine is well tolerated over a one-year period and produces more improvement in immunologic and virologic measures than does treatment with either agent alone.
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection.
TLDR
The protease inhibitor ritonavir is well tolerated and has a potent antiviral effect, as shown by substantial decreases in plasma viremia and significant elevations in CD4 cell counts.
Lamivudine Plus Zidovudine Compared with Zalcitabine Plus Zidovudine in Patients with HIV Infection
TLDR
This NUCA 3002 study was designed to compare the safety and activity of two doses of lamivudine plus zidovudine in patients with moderately advanced HIV infection who had previously received zidvudine, and to encourage further evaluation of antiretroviral drug combinations for the treatment of HIV infection.
Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
TLDR
In symptomatic HIV-infected children, treatment with eitherdidanosine alone or zidovudine plus didanosine was more effective than treatment with zidvudine alone and was associated with less hematologic toxicity.
Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients : A randomized controlled comparison with zidovudine monotherapy
TLDR
The combination of lamivudine and zidovudine results in a potent and sustained antiviral effect in antiretroviral-naive patients that is superior to that observed with zidvudine monotherapy.
Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
TLDR
In zidovudine-experienced HIV-1-infected patients, combination treatment with lamivudine and zidavudine is well tolerated and provides greater and more sustained increases in CD4+ cell counts and decreases in viral load than continued zidvudine monotherapy.
...
1
2
3
4
5
...